Avoidant/restrictive food intake disorder (ARFID) is a serious and impairing eating disorder - occurring in up to 4% of adults - for which most individuals do not have access to treatment. The proposed study aims to develop and test a mobile app to scale delivery of cognitive-behavioral therapy for ARFID. Knowledge gained will contribute to the development of a clinically accessible, scalable, inexpensive treatment for ARFID, a highly impairing disorder for which there are significant barriers to care access.
Current avoidant/restrictive food intake disorder based on DSM-5 criteria
Must not have completed face-to-face CBT-AR at the Eating Disorders Clinical and Research Program at Massachusetts General Hospital
Ability to speak, write, and understand English
Residence in the United States
Underweight status (i.e., BMI < 18.5 kg/m2)
Complete lack of oral intake or dependence on supplemental feeding
Feeding or eating disorder other than ARFID
Any comorbid clinically significant disorder that would require attention beyond the study treatment
Parallel
mCBT-AR
BehavioralmCBT-AR is an 8-week virtual treatment for avoidant/restrictive food intake disorder delivered via mobile application
Pica, ARFID, and Rumination Disorder Interview - ARFID Questionnaire (PARDI-AR-Q)
The PARDI-AR-Q is a 32-item self-report measure based on the Pica, ARFID, and Rumination Disorder Interview that assesses ARFID diagnostic criteria and the presence and severity of each ARFID profile. Severity scores for each profile range from 0-6, with higher scores indicating greater severity.
Food Neophobia Scale (FNS)
The Food Neophobia Scale is a 6-item measure that measures reluctance to try new foods. Scores range from 7-42. Higher scores on the FNS are indicative of greater behavioral responses to novel foods.
Click on the lead sponsor to view all of their trials.
